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Anaemia is common in patients with cancer and contributes to the
morbidity associated with this disease. Although patients with
cancer may have factors such as chemotherapy, radiotherapy,
haemolysis, bleeding, poor nutrition or bone marrow infiltration
contributing to anaemia, for most patients, the anaemia is
primarily due to the erythropoietic aberrations associated with
chronic disease. The anaemia of chronic disease is associated with
both a relative endogenous erythropoietin (EPO) deficiency
(Miller et al, 1990; Ozguroglu et al, 2000) and a blunted erythro-
poietic response to EPO, probably caused by inflammatory
cytokines (Jelkmann, 1998). 
Anaemia is associated with numerous symptoms, including
depression, impaired cognitive function, and fatigue, which is a
primary complaint of patients receiving chemotherapy (Ludwig
and Fritz, 1998). Treatment options for anaemia in patients with
cancer not receiving chemotherapy include administration of red
blood cell transfusions if the anaemia is severe, or watchful
waiting if the anaemia is mild or moderate. 
Several studies have examined recombinant human erythro-
poietin (rHuEPO) in the treatment of the chronic anaemia of
cancer not associated with chemotherapy. Administration
improved haematocrit or haemoglobin values after 8 to 12 weeks
of treatment in patients with anaemia due to cancer in the absence
of concomitant chemotherapy (Abels et al, 1991; Ludwig et al,
1994). However, these studies failed to show statistically signifi-
cant reductions in the number of red blood cell transfusions
needed, probably because the studies were inadequately powered
to detect a benefit or because the dose and length of study were not
sufficient to achieve the desired effect. In a separate study, Henry
and Abels (1994) demonstrated significant decreases in trans-
fusion requirements of anaemic patients not receiving chemotherapy
after 6 months of treatment. All studies required administration of
100 to 150 U kg–1 rHuEPO as a subcutaneous injection three times
per week under the supervision of a physician. In most studies, a
single dose increase was permitted for non-responding patients.
The dose–response relationship for rHuEPO used in this setting
has not been fully characterized. 
Darbepoetin alfa is a novel erythropoiesis stimulating protein
(NESP) that stimulates erythropoiesis in the same manner as
rHuEPO. NESP is biochemically distinct from rHuEPO. It has
additional sialic acid that has been shown to confer an increased
terminal half-life in animal models, patients with chronic renal
Novel erythropoiesis stimulating protein (NESP) for the
treatment of anaemia of chronic disease associated
with cancer 
RE Smith, Jr1, IA Jaiyesimi2, LA Meza3, NS Tchekmedyian4, D Chan5, H Griffith6, S Brosman7, R Bukowski8,
M Murdock9, M Rarick10, A Saven11, AB Colowick12, A Fleishman13, U Gayko14 and J Glaspy15
1South Carolina Oncology Associates, 1301 Taylor, Suite IA, Columbia, SC 29201, USA; 2William Beaumont Hospital, 3577 West 13 Mile Road, Suite 404,
Royal Oak, MI 48073, USA; 3Southwest Oncology Associates, 443 Heymann Blvd, Suite A, Lafayette, LA 70503, USA; 4Pacific Shores Medical Group Inc, 1043
Elm Ave, Suite 104, Long Beach, CA 90813-3244, USA; 5Cancer Care Associates Medical Group, 514 North Prospect St, Redondo Beach, CA 90277-3026,
USA; 6Memorial Clinic Research Center, 520 Lilly Road, NE, Building 3, Olympia, WA 98506, USA; 7Pacific Clinical Research, 1260 15th Street, Suite 1200,
Santa Monica, CA 90404, USA; 8The Cleveland Clinic Foundation, Desk S33, 9500 Euclid Avenue, Cleveland, OH 44195, USA; 9Urology Associates, 7500
Hanover Parkway, Suite 206, Greenbelt, MD 20770, USA; 10Kaiser Permanente Northwest Division, 3600 North Interstate, Portland, OR 97227, USA; 11Scripps
Clinic, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA; 12Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA; 13Amgen Inc,
One Amgen Center Drive, M/S 24-1-C, Thousand Oaks, CA 91320-1799, USA; 14Amgen Inc., One Amgen Center Drive; M/S 24-1-C, Thousand Oaks, CA
91320-1799, USA; 15UCLA School of Medicine, 200 Medical Plaza, Suite 120, Los Angeles, CA 90024, USA 
Summary Anaemia is a common haematologic disorder in patients with cancer and has a multifactorial aetiology, including the effects of the
malignancy itself and residual effects from previous therapy. Novel erythropoiesis stimulating protein (NESP, darbepoetin alfa), a protein with
additional sialic acid compared with erythropoietin (EPO), stimulates erythropoiesis by the same mechanism as recombinant human
erythropoietin (rHuEPO) but it is biochemically distinct. NESP, with its approximately 3-fold greater serum half-life, can maintain haemoglobin
levels as effectively as rHuEPO in anaemic patients with chronic renal failure and do so with less frequent dosing. We investigated the ability
of NESP to safely increase haemoglobin levels of anaemic patients with non-myeloid malignancies not receiving chemotherapy. NESP was
administered under the supervision of a physician at doses of 0.5, 1.0, 2.25 or 4.5 mcg kg–1 wk–1 for a maximum of 12 weeks. This report
includes 89 patients completing the study by November 2000. NESP was well tolerated, with no reported dose-limiting toxicities or treatment-
related severe adverse events. Increasing doses of NESP corresponded with increased efficacy. The percentage (95% confidence interval)
of patients responding ranged from 61% (42%, 77%) in the 1.0 mcg kg–1 wk–1 group to 83% (65%, 94%) in the 4.5 mcg kg–1 wk–1 group. 
© 2001 Cancer Research Campaign 
Keywords: anaemia; cancer; chemotherapy; chronic disease; darbepoetin alfa; erythropoietin 
24
Correspondence to: J Glaspy 
British Journal of Cancer (2001) 84 (Supplement 1), 24–30
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.1749, available online at http://www.idealibrary.com on 
This study was supported by Amgen Inc, Thousand Oaks, California. NESP in chronic anaemia of cancer 25
British Journal of Cancer (2001) 84(Supplement 1), 24–30 © 2001 Cancer Research Campaign
failure, and cancer patients receiving multiple cycles of
chemotherapy (Egrie et al, 1997; Macdougall et al, 1999; Glaspy
et al, 2000). Increasing the half-life of active drug may confer a
clinical advantage by allowing less frequent dosing and main-
taining stable haemoglobin levels, attributes that are potentially
valuable in chronic indications. Animal studies have indicated that
NESP can alleviate the anaemia of chronic disease (Cooke et al,
2000), a model for one type of anaemia seen in cancer patients not
receiving chemotherapy. 
The purpose of this study was to assess the safety of NESP
administered by subcutaneous injection one time per week to
patients with chronic anaemia who were not receiving chemo-
therapy and to determine the clinically effective doses of NESP in
this setting during a 12-week treatment phase, and to begin to
characterize the dose–response relationship. Additionally, the
effects of NESP on health-related quality of life were assessed
using the FACT-Fatigue scales (Cella, 1997). 
PATIENTS AND METHODS 
Patients 
The institutional review boards of the participating centres
approved the protocol, and patients gave written informed consent
before the study was started. Patients who were at least 18 years of
age with non-myeloid malignancy and anaemia (haemoglobin
≤ 11.0 g dl–1), and who were not currently receiving or planning to
receive cytotoxic chemotherapy or external beam radiotherapy
within 16 weeks were eligible to enrol. Other key eligibility
criteria included Eastern Cooperative Oncology Group (ECOG)
performance status of 0 to 2, platelet count ³ 50 ´ 109 l–1, and
anaemia predominantly resulting from cancer or previous treat-
ment with chemotherapy or radiotherapy. All patients were
required to have adequate iron stores, and adequate liver and renal
function. Patients were excluded from enrolment if they had a
primary or metastatic malignancy involving the central nervous
system, had active bleeding or haemolysis, had received
chemotherapy within 8 weeks of enrolment, had received red
blood cell transfusions within 16 days of enrolment, had an
unstable medical condition (e.g. angina, arrhythmia, hypertension,
clinically significant systemic infection or chronic inflammatory
disease other than cancer), or had a primary haematologic disorder
that could cause anaemia. 
Study drug 
Novel erythropoiesis stimulating protein (NESP) (darbepoetin
alfa, ARANESP™, Amgen Inc, Thousand Oaks, CA) is purified
from cell culture medium of a NESP-expressing Chinese hamster
ovary (CHO) cell line (Egrie et al, 1997). NESP was provided in a
liquid formulation, containing per ml: 0.25% human serum
albumin, 140 mM sodium chloride and 20 mM sodium phosphate. 
Study design 
This was an open-label, sequential dose-escalation, dose-finding
study for treatment of patients with chronic anaemia of cancer.
NESP was administered under the supervision of a physician as a
subcutaneous injection once per week (NESP 0.5, 1.0, 2.25 or 4.5
mcg kg–1 wk–1) commencing on study day 1 (within 3 days of
study enrolment) and administered on the same day of the week
throughout the 12-week dosing period. Standard tests and observa-
tions were performed throughout the dosing period (i.e. weekly
complete blood counts and monthly coagulation, blood chemistry,
serum iron, iron-binding capacity, ferritin and transferrin satura-
tion). Additional monthly blood samples were collected for anti-
body testing. Patients were permitted to receive red blood cell
transfusions as clinically indicated and transfusions were recom-
mended if the patient’s haemoglobin decreased to ≤ 8.0 g dl–1. 
The follow-up period started immediately after the last dose of
study drug administration and continued for 4 weeks. The same
standard tests and observations were performed during this period. 
A health-related quality of life questionnaire was completed by
patients every 2 weeks during the 16-week study. The question-
naire contained the FACT-G and the FACT-Anaemia scales. The
FACT-Fatigue scale, reported in this paper, is a component of the
FACT-Anaemia scale. 
Dose adjustments 
The dosage of NESP was initially reduced to the next lowest dose
level if a patient’s haemoglobin increased ³ 2.0 g dl–1 in the
previous 28-day period in the absence of red blood cell trans-
fusion. With the implementation of a protocol amendment, NESP
was reduced to the next lowest dose based on these criteria, but
only if the patient’s haemoglobin was above 13.0 g dl–1. Patients in
the NESP 0.5 and 1.0 mcg kg–1 wk–1 cohorts were enrolled before
this amendment and patients in the NESP 2.25 and 4.5 mcg 
kg–1 wk–1 cohorts were enrolled after this amendment. NESP was
withheld if the haemoglobin value was > 15.0 g dl–1 for men or 
> 14.0 g dl–1 for women. NESP could be reinstated at the next
lowest dose level if the haemoglobin value subsequently decreased
to < 13.0 g dl–1. Only one dose reduction per patient was permitted.
Safety endpoints 
Safety was monitored on an ongoing basis during the study period
and consisted of adverse event reports, concomitant medications,
laboratory tests and vital signs. Serum samples were tested at
monthly intervals using a standard test to detect the development,
if any, of antibodies to NESP. 
Efficacy endpoints 
The efficacy of NESP was assessed based on the proportion of
patients who achieved a haemoglobin response, defined as a
³ 2.0 g dl–1 increase from the baseline haemoglobin in the absence
of a red blood cell transfusion within the preceding 28 days.
Haemoglobin correction, defined as a post-baseline haemoglobin
value ³ 12.0 g dl–1 in the absence of a red blood cell transfusion
within the preceding 28 days, was also measured. Furthermore,
change in baseline haemoglobin compared with week 4 and the
end of treatment, incidence of red blood cell transfusions from
week 5 to the end of treatment, time to haemoglobin response, and
time to haemoglobin correction were assessed. In addition, the
feasibility, reliability and validity of the quality of life question-
naire (FACT-Fatigue) in this setting was assessed. 
Statistical analysis 
All patients who received at least one dose of NESP were evalu-
able for the efficacy and safety analyses. Data were analysed by26 RE Smith et al 
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dose cohort. Descriptive statistics summarized demographic and
baseline data (for categorical data: number of subjects, percent-
ages; for continuous data: mean, standard deviation (SD), median,
minimum and maximum). The mean and 95% confidence interval
(based on the normal approximation) were calculated for the
change in haemoglobin from baseline to week 4 and to end of
treatment. If the week 4 or end of treatment visit occurred within
28 days of a red blood cell transfusion or was missing, the last
haemoglobin value before this visit was used (if no red blood cell
transfusion had been given within the previous 28 days).
Proportions and 95% confidence intervals (based on the
Clopper–Pearson method) were calculated for the incidence of
haemoglobin response, haemoglobin correction, and number of
red blood cell transfusions from weeks 5 through 12.
Kaplan–Meier plots were generated for time (week) to haemo-
globin response and haemoglobin correction. 
Health-related quality of life data were analysed by haemo-
globin response (< 0 g dl–1, 0 to 2 g dl–1 and > 2 g dl–1 change in
haemoglobin) at the end of the 12-week study. 
RESULTS 
Patient disposition and baseline characteristics 
This study was conducted at 10 sites with one site encompassing a
network of approximately 20 active satellite sites. One hundred
and five patients were enrolled into the study; 89 had completed
the study by November 2000, and their data are included in this
report. Of these 89 patients, 87 (98%) received at least one dose of
study drug (NESP 0.5 mcg kg–1 wk–1, n = 6; NESP 1.0 mcg kg–1
wk–1, n = 33; NESP 2.25 mcg kg–1 wk–1, n = 18; NESP 4.5 mcg
kg–1 wk–1, n = 30). Two patients in the 2.25 mcg kg–1 wk–1 cohort
did not receive NESP and are not included in the efficacy or safety
analyses. Limited conclusions can be drawn from the NESP 0.5 mcg
kg–1 wk–1 dose cohort because of the small sample size (n = 6), but
the data are presented for completeness. Of the 87 patients who
received at least one dose of study drug, the mean (SD) age was 70.3
(12.0) years; 55% were men; the most common tumours were breast
and genitourinary; most patients had an ECOG status < 2; and the
mean (SD) baseline haemoglobin was 9.87 (1.01) g dl–1 (Table 1). 
Overall, 78% of the 87 patients completed the 12-week dosing
regimen per protocol: 67%, 73%, 78% and 87% in the NESP 0.5,
1.0, 2.25 and 4.5 mcg kg–1 wk–1 cohorts, respectively. Reasons for
not completing study included death (3%), adverse events (2%)
and miscellaneous (1% to 4% each). 
Study drug dose adjustment 
None of the patients in the NESP 0.5 mcg kg–1 wk–1 group, 10
(30%) in the NESP 1.0 mcg kg–1 wk–1 group, 3 (17%) in the NESP
2.25 mcg kg–1 wk–1 group and 6 (20%) in the NESP 4.5 mcg kg–1
wk–1 group had their dose of NESP reduced because of a rapid
Table 1 Patient baseline demographics and clinical characteristics 
NESP (mcg kg–1 wk–1) 
0.5 1.0 2.25 4.5 ALL NESP 
(n = 6) (n = 33)  (n = 18) (n = 30) (n = 87) 
Age, years 
Mean (SD) 53.2 (8.6) 69.7 (13.5) 71.1 (9.5)  74.0 (9.1) 70.3 (12.0) 
Sex, n (%) 
Female 5 (83.3%) 14 (42.4%) 8 (44.4%) 12 (40.0%) 39 (44.8%) 
Male 1 (16.7%) 19 (57.6%) 10 (55.6%)  18 (60.0%) 48 (55.2%) 
Primary site of disease, n (%) 
Breast 4 (66.7%) 9 (27.3%) 4 (22.2%)  7 (23.3%) 24 (27.6%) 
Lung 1 (3.0%) 2 (11.1%) 2 (6.7%) 5 (5.7%) 
Gastrointestinal 2 (6.1%) 2 (11.1%)  4 (13.3%) 8 (9.2%) 
Gynaecologic 1 (3.0%) 1 (3.3%)  2 (2.3%) 
Genitourinary 1 (16.7%) 11 (33.3%) 4 (22.2%) 12 (40.0%) 28 (32.2%) 
Other solid tumour 1 (16.7%) 3 (9.1%) 1 (3.3%) 5 (5.7%) 
Lymphoid malignancy 6(18.2%) 6 (33.3%) 3 (10.0%) 15 (17.2%) 
ECOG, n (%) 
0 2 (33.3%) 11 (33.3%) 8 (44.4%)  7 (23.3%) 28 (32.2%) 
1 3 (50.0%) 17 (51.5%) 8 (44.4%)  18 (60.0%) 46 (52.9%) 
2 1 (16.7%) 5 (15.2%) 2 (11.1%)  5 (16.7%) 13 (14.9%) 
Hgb, g dl–1
Mean (SD) 9.60 (1.53) 9.80 (0.91)  9.80 (1.14) 10.05 (0.94) 9.87 (1.01) 
Median 9.65 9.90 10.05 10.45 10.10 
Min, Max 7.4, 11.4 7.3, 11.0 7.4, 11.2  7.8, 11.4 7.3, 11.4 
Endogenous EPO, mU ml–1
Mean (SD) 65.71 (80.41) 45.68 (42.48)  56.48 (49.04) 41.76 (56.77) 48.30 (50.65)
Median 29.73 31.05 36.79 26.01 29.90 
Min, Max 12.0, 206.6 12.0, 180.7 12.0, 163.9  12.0, 278.5 12.0, 278.5 
ECOG = Eastern Cooperative Oncology Group performance status; EPO = erythropoietin; Hgb = haemoglobin; SD = standard
deviation. NESP in chronic anaemia of cancer 27
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increase in haemoglobin. The higher dose reduction rate in the
NESP 1.0 mcg kg–1 wk–1 group compared with either the rate in the
NESP 2.25 or the NESP 4.5 mcg kg–1 wk–1 group can probably be
explained by the fact that the latter 2 cohorts were enrolled after
the amendments to the protocol re-defined dose reduction in
response to rapid increases in haemoglobin. None of the patients in
either the NESP 0.5 or the NESP 1.0 mcg kg–1 wk–1 groups, 6
(33%) patients in the NESP 2.25 mcg kg–1 wk–1 group, and 11
(37%) patients in the NESP 4.5 mcg kg–1 wk–1 group had their dose
of study drug withheld because their haemoglobin values were 
> 14.0 g dl–1 (women) or > 15.0 g dl–1 (men). 
Safety results 
At the time of this report, 87 patients were evaluable for safety.
Eighty-six (99%) patients reported at least one adverse event. The
most frequently reported adverse events were fatigue, asthenia,
fever, peripheral oedema, pain and influenza-like symptoms. Nine
(10%) of the adverse events were reported as treatment-related.
Twenty patients (23%) experienced serious adverse events that
were reported by the investigator as not related to treatment. Seven
(8%) of the adverse events resulted in discontinuation of study;
none of these events were reported as related to treatment. Five
(6%) patients died while on study, and all deaths were attributed to
disease progression and reported as not related to treatment. Aside
from the expected increase in erythropoietic elements, laboratory
findings were consistent with the population studied. All patients
who received study drug had at least one post-baseline sample
tested for antibodies to NESP. None of these samples were reac-
tive, indicating that no antibodies to NESP had been detected. No
unexpected trends were seen that suggested a drug-related adverse
effect and no dose-related relationships were apparent for reported
adverse events. No clinically significant changes in vital signs
were noted for any cohort. 
Efficacy results 
Because of the small sample size (n = 6), the NESP 0.5 mcg kg–1
wk–1 cohort is not discussed, but the data are presented in figures
and tables. 
Figure 1 demonstrates a dose-dependent relationship between
NESP and the proportion of patients achieving a haemoglobin
response and haemoglobin correction. In panel A, the percentage
of patients who achieved a haemoglobin response is plotted for
each cohort. Patients who received at least one dose of study drug
had a response rate (95% confidence interval) of 61% (42%, 77%),
67% (41%, 87%) and 83% (65%, 94%) in the NESP 1.0, 2.25 and
4.5 mcg kg–1 wk–1 groups, respectively. Panel B of Figure 1 shows
the percentage of patients who achieved a haemoglobin correction.
The correction rate (95% confidence interval) for patients who
received at least one dose of NESP was 61% (42%, 77%), 72%
(47%, 90%), and 80% (61%, 92%) in the NESP 1.0, 2.25 and 4.5
mcg kg–1 wk–1 cohorts, respectively, suggesting a dose–response
relationship. All doses studied met the predefined criteria for 
clinical efficacy (i.e. at least 50% of patients achieving a 2 g dl–1
increase in haemoglobin over baseline). 
The analysis of change from baseline haemoglobin also
suggests a dose–response relationship (Table 2). The mean change
at week 4 (95% confidence interval) for patients receiving at least
one dose of study drug was 0.68 (0.22, 1.14), 0.84 (0.22, 1.46) and
1.26 (0.85, 1.67) in the NESP 1.0, 2.25 and 4.5 mcg kg–1 wk–1
cohorts, respectively. By the end of treatment, the mean change
Table 2 Change from baseline haemoglobin and red blood cell transfusion 
NESP (mcg kg–1 wk–1) 
0.5 1.0 2.25 4.5 
Change from baseline 
haemoglobin at week 4, g dl–1
Mean (95% Cl) –0.10 0.68 0.84  1.26 
(–1.08, 0.88) (0.22, 1.14) (0.22, 1.46) (0.85, 1.67) 
Change from baseline 
haemoglobin at the end of treatment, g dl–1
Mean (95% Cl) 1.45 1.71 2.63  2.91 
(–0.52, 3.42) (0.91, 2.52) (1.54, 3.71) (2.17, 3.65) 
RBC transfusions from week 5 
to the end of treatment 
Number of patients (n)1 8 3  2  
Percent of patients (95% Cl) 17 24 17  7 
(0, 64) (11, 42) (4, 41) (1, 22) 
Cl = confidence interval. 
Note: Post-baseline haemoglobin values that occurred within 28 days of a red blood cell transfusion were excluded in
calculating the mean. The last value was carried forward for patients without a valid week 4 or end of treatment
haemoglobin value. 
Table 3 Health-related quality of life change from baseline to week 12 by
haemoglobin change 
HRQOL SCORE Hgb<0 g dl–1 Hgb 0 to 2 g dl–1 H g b>2gd l –1
FACT-Fatigue 
Mean –5.2 6.9 9.0 
Median –2.5 4.5 7.0 
SD 10.7 9.7 10.8 
Quartiles –8.0, 0.0 1.0, 11.0  2.0, 15.0 
Range –27.0, 10.0 –3.0, 31.0  –10.0, 36.0 
n 10 10 46 
HRQOL = health-related quality of life; Hgb = haemoglobin. 28 RE Smith et al 
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Figure 1 The percentage of patients with a haemoglobin response (panel A) and haemoglobin correction (panel B) with exact 95% confidence intervals NESP in chronic anaemia of cancer 29
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(95% confidence interval) increased to 1.71 (0.91, 2.52), 2.63
(1.54, 3.71) and 2.91 (2.17, 3.65). 
Similarly, the incidence of red blood cell transfusions from
week 5 to the end of treatment also suggests a dose–response
relationship. The transfusion rates (95% confidence interval) for
patients receiving at least one dose of study drug were 24% (11%,
42%), 17% (4%, 41%) and 7% (1%, 22%) in the NESP 1.0, 2.25
and 4.5 mcg kg–1 wk–1 cohorts, respectively. 
We also investigated the impact of dose on the time required for
response. Figure 2 illustrates the relationship between parameters
of efficacy over time. A consistent trend is observed with respect
to the rapidity of achieving the desired endpoints of response
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Figure 2 Kaplan–Meier estimate of the cumulative percent of patients responding (panel A) and correcting (panel B) over study weeks. The NESP dose
cohorts studied were 0.5(l), 1.0(n), 2.25 (s), and 4.5 (H) mcg kg–1 wk–1. The n’s represent the number of patients who have yet to achieve the endpoint or
become censored at the start of each study week. An ‘l’ on the plot indicates a censored observation. The vertical dashed lines at weeks 4, 8 and 13 are 95%
confidence intervals of the cumulative percents at these time points 30 RE Smith et al 
British Journal of Cancer (2001) 84(Supplement 1) , 24–30 © 2001 Cancer Research Campaign
(panel A) or correction (panel B). The median time to achieving
any of these endpoints was shortest with the higher doses. 
Quality of life findings 
The relationship between improvements in haemoglobin and
improvement in subject self-reported fatigue, as measured by the
FACT-Fatigue scale, is shown in Table 3. The difference between
patients whose haemoglobin decreased and patients whose haemo-
globin increased by > 2.0 g dl–1 was 14.2 points on the FACT-
Fatigue scale. 
DISCUSSION 
Chronic anaemia of cancer is a common clinical problem for
which no treatment is currently approved other than red blood cell
transfusions. RHuEPO has been used off-label in this setting, but
the published data are not clear with respect to a dose–response
relationship for rHuEPO in this setting. In addition, because of the
chronic nature of this condition, attributes consistent with less
frequent administration would be desirable. In recent studies,
NESP has been shown to have an increased terminal half-life and
the ability to ameliorate anaemia in cancer patients undergoing
multiple cycles of chemotherapy. The current study was under-
taken to explore the safety and efficacy of multiple doses of NESP
in patients not receiving chemotherapy who have chronic anaemia
of cancer. 
In this study, NESP was safe and well tolerated at doses from
0.5 to 4.5 mcg kg–1 wk–1 when administered weekly by subcuta-
neous injection. The safety profile for NESP is generally similar to
that reported for rHuEPO with adverse events predominantly due
to the underlying medical condition of patients with cancer. 
In patients with chronic anaemia of cancer, at all doses tested,
NESP demonstrated clinical activity, with apparent dose–response
relationships, for all efficacy parameters. NESP, when adminis-
tered once-weekly over a 12-week period, increased haemoglobin
values ³ 2.0 g dl–1 over baseline in ³ 60% of all patients treated at
each dose tested. These rates are comparable to the 62% haemo-
globin response rate (Ludwig et al, 1995) and the 63.5% haema-
tocrit response rate (Abels et al, 1991: Ludwig et al, 1994)
reported in a similar patient population after 12 weeks of dosing
three times weekly with rHuEPO (100 to 150 U kg–1). The higher
doses (2.25 and 4.5 mcg kg–1 wk–1) of NESP tested in this study
appear to produce a higher response rate in this group of patients
than the rate that has been historically reported. This is likely due
to a robust dose–response relationship of erythropoietic agents in
this setting. The lack of a control group in this study, however,
limits the ability to draw firm conclusions in this regard. 
Anaemia has been shown to be a major factor in the fatigue and
decreased quality of life observed in cancer patients. Ameliorating
anaemia with its attendant morbidity more rapidly is a desired goal
of therapy. Importantly, our time to response or correction analysis
suggests that higher dosing with NESP early in the course of treat-
ment may result in a more rapid response. This is a unique obser-
vation and, if confirmed in future studies, has obvious implications
for the use of this agent in patients who are significantly impaired
by fatigue. 
This study has limitations. The lack of a control group makes it
difficult to compare the results of this study with others in the
literature using rHuEPO as the treatment. In addition, it cannot be
firmly concluded that the results seen in this study are different
from what would be observed with placebo therapy. However, this
seems unlikely given the dose-dependent relationships that were
observed for most measures of efficacy and given the high rates of
response seen in this study compared with what would be expected
from historical controls. The open-label nature of this study calls
into question the results observed in the self-reported health-
related quality of life measurements. However, this portion of the
study was intended primarily to assess the feasibility and timing of
measuring health-related quality of life in this patient population.
Finally, the weekly administration of NESP should be compared
with less frequent dosing, a schedule that seems plausible given
the high response rates observed in this study. These results
suggest that more rigorous, placebo-controlled studies that explore
longer dose intervals and confirm the dose–response and time to
response findings are warranted. 
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